ENDRA Life Sciences Inc. (NDRA)

In the past six months, ENDRA's stock has been impacted by several events. The Board of Directors initiated a review of strategic alternatives to maximize shareholder value due to financial headwinds. Positive clinical study results for the TAEUS® Liver Device were announced, demonstrating high-level consistency. The share price experienced a decline of 20.14% from March 24, 2025, to March 20, 2026. Shareholders experienced substantial dilution, with total shares outstanding increasing by 117.3%. The company reported a net loss in its latest quarter, with earnings per share (EPS) worse than previous estimates.

There is no readily available information indicating demand seasonality for ENDRA Life Sciences, Inc.'s products and services. Demand for its TAEUS® system is primarily driven by clinical adoption, regulatory approvals, and integration into healthcare practices and pharmaceutical research.

ENDRA Life Sciences, Inc. is a medical technology company focused on enhancing clinical diagnostic ultrasound capabilities. Their primary product, the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, aims to visualize tissue with MRI-like quality at a lower cost. TAEUS® is initially focused on measuring fat in the liver to assess steatotic liver disease (SLD) and is being explored for other clinical uses. The company also offers the Nexus 128 system for lab researchers.

ENDRA Life Sciences, Inc. is headquartered in Ann Arbor, Michigan, USA. Its TAEUS® technology is designed to integrate with global ultrasound systems, addressing a worldwide patient population. The company holds European and U.S. patents for its TAEUS® system.

ENDRA Life Sciences' brand reputation has been shaped by both positive technological advancements and financial challenges. The company has garnered positive attention for its TAEUS® Liver device, which has demonstrated high-level consistency in clinical studies. Despite technological progress, the company has faced reputational challenges due to its financial situation, including a rapid cash burn and unprofitability, contributing to market skepticism.

ENDRA Life Sciences Inc. has a mix of institutional and individual ownership. Institutional investors and shareholders held a total of 71,825 shares as of March 26, 2026, with major holders including Altium Capital Management LP, Vanguard Group Inc, and Morgan Stanley. Individual insiders collectively hold 6.08% of the shares (70,912 shares), while the general public holds the largest portion at 87.2% (1,017,030 shares).